We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Corteva, Inc. (CTVA) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Corteva, Inc. (CTVA - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.09 per share, reflecting an increase of 139.1% compared to the same period last year. Revenues are forecasted to be $1.77 billion, representing a year-over-year decrease of 32.4%.
The consensus EPS estimate for the quarter has undergone a downward revision of 7.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Corteva, Inc. metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Crop Protection' will reach $1.79 billion. The estimate points to a change of +5% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Seed' reaching $840.59 million. The estimate indicates a change of -8.3% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Crop Protection- Fungicides' will reach $237.32 million. The estimate suggests a change of +6.9% year over year.
The consensus estimate for 'Net Sales- Crop Protection- Other' stands at $113.21 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Crop Protection- Biologicals' will likely reach $157.96 million. The estimate points to a change of +7.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Crop Protection- Herbicides' of $853.66 million. The estimate points to a change of +5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Crop Protection- Insecticides' should come in at $454.34 million. The estimate points to a change of +11.1% from the year-ago quarter.
The average prediction of analysts places 'Operating EBITDA- Crop Protection' at $267.01 million. The estimate compares to the year-ago value of $279.00 million.
Over the past month, shares of Corteva, Inc. have returned -12.4% versus the Zacks S&P 500 composite's -5.4% change. Currently, CTVA carries a Zacks Rank #5 (Strong Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for Corteva, Inc. (CTVA) Q3 Earnings: Wall Street Estimates for Key Metrics
In its upcoming report, Corteva, Inc. (CTVA - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.09 per share, reflecting an increase of 139.1% compared to the same period last year. Revenues are forecasted to be $1.77 billion, representing a year-over-year decrease of 32.4%.
The consensus EPS estimate for the quarter has undergone a downward revision of 7.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Corteva, Inc. metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Crop Protection' will reach $1.79 billion. The estimate points to a change of +5% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Seed' reaching $840.59 million. The estimate indicates a change of -8.3% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Crop Protection- Fungicides' will reach $237.32 million. The estimate suggests a change of +6.9% year over year.
The consensus estimate for 'Net Sales- Crop Protection- Other' stands at $113.21 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Crop Protection- Biologicals' will likely reach $157.96 million. The estimate points to a change of +7.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Crop Protection- Herbicides' of $853.66 million. The estimate points to a change of +5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Crop Protection- Insecticides' should come in at $454.34 million. The estimate points to a change of +11.1% from the year-ago quarter.
The average prediction of analysts places 'Operating EBITDA- Crop Protection' at $267.01 million. The estimate compares to the year-ago value of $279.00 million.
View all Key Company Metrics for Corteva, Inc. here>>>Over the past month, shares of Corteva, Inc. have returned -12.4% versus the Zacks S&P 500 composite's -5.4% change. Currently, CTVA carries a Zacks Rank #5 (Strong Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .